Mylan: The Deterioration Continues

|
About: Mylan N.V. (MYL), Includes: TEVA
by: Shock Exchange
This article is exclusive for subscribers.
Shock Exchange
Long/short equity, long only, short only, special situations
Summary

MYL's Q4 revenue and EBITDA were off 5% and 12%, respectively.

The company's core generics business continues to deteriorate and the EpiPen could face headwinds from generic competition.

MYL is off over 50% Y/Y and will likely fall further.

Sell MYL.

Mylan CEO Heather Bresch. Source: Houston Chronicle

Mylan (MYL) reported Q4 revenue of $3.08 billion and non-GAAP EPS of $1.30. The company beat on revenue by $20 million, but missed on non-GAAP. MYL